Evolutec reports positive pharmacokinetic profile for rEV131

By Lisa Kerner

Erie, Pa., Feb. 27 - Evolutec Group plc said a preclinical study demonstrates that its molecule, rEV131, has a favorable pharmacokinetic profile including a circulating half-life of about eight hours, uniform tissue distribution and 95% clearance from the body within 24 hours.

Additionally, the trial showed that rEV131, a histamine-binding protein, does not cross the blood brain barrier, reducing the possibility of unwanted effects such as drowsiness.

According to a company news release, this profile is well suited for a drug intended for use once or twice a day in indications such as allergic rhinitis (hay fever) and asthma.

"This result underpins the potential of rEV131, our lead drug product candidate," chief executive officer Mark Carnegie Brown said in the release.

"It also endorses Evolutec's technology and approach, which is based around proteins sourced from the saliva of ticks."

In 2005, Evolutec announced a positive result for rEV131 in a 112-patient phase 2a proof-of-concept study in allergic rhinitis whereby rEV131 met the primary efficacy endpoint and showed efficacy against mucus and congestion.

Evolutec said it plans additional proof-of-concept phase 2 trials with rEV131 in post-cataract surgery and dry eye.

Evolutec is a biopharmaceutical company developing drugs for allergy, inflammation and autoimmune disease. The company is based in Reading, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.